PJ-011726 IntelliSpace Cognition MCI Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
New York
-
Amherst, New York, United States, 14226
- Dent Neurologic Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged 50-80
- Patient is able to give consent
- MCI or amnestic MCI diagnosis by a clinical specialist, such as a neurologist - diagnosis not older than 12 months prior to inclusions date.
- If 3D T1 MRI images are present they cannot be older than 6 months prior to the MCI clinical diagnosis was made.
- Must be proficient in American English.
- If patient has vision impairment or hearing loss, must be corrected to normal.
- Must have use of fingers, hands, and arms to be able to use a pencil to write symbols.
- Must be able to understand test instructions and participate fully in testing.
Exclusion Criteria:
- Currently admitted to a hospital, assisted living, nursing home or a psychiatric facility.
Diagnosed with a (neurological) disorder other than MCI or aMCI, i.e.:
- Current primary neurodegenerative diseases (e.g., Parkinson's disease, brain tumor, dementia)
- Stroke
- Current TBI
- Current epilepsy [if # seizures ≤ 2 and not receiving ongoing treatment for seizures, and not currently seeking medical evaluation or attention related to seizures, patient can be accepted],
- Current encephalitis
- Current language disorder (expressive or mixed receptive/expressive excluded; articulation disorder is ok)
- Current learning disorder
- Current or past psychotic disorder
- Current severe mood disorder (in the case of Major Depressive Disorder in remission or with no current episode, and Dysthymic and Adjustment disorder, examinee can be accepted)
- Current severe anxiety disorder (e.g., PTSD, GAD, OCD) with symptoms significant enough to interfere with optimal test performance (in the case of phobias, examinee can be accepted)
- Current or past Autism Spectrum Disorder or Intellectual Disability
- Primarily nonverbal or uncommunicative
- Current aphasia
- LUPUS
- Multiple Sclerosis
- Sleep apnea (moderate or severe, Apnea-Hypopnea Index <15 is acceptable)
Major structural intracranial abnormalities and brain disorders on prior imaging study (in the last 12 months), i.e.:
- Major developmental disorders (e.g., polymicrogyria, schizencephaly)
- Intracranial tumors: intraaxial (brain tumors); extraaxial (tumors of bone and meninges) insofar they exert mass effect on the brain with edema or gliosis
- Chronic brain injury and acquired focal or diffuse loss of normal parenchyma regardless of the etiology (e.g. prior stroke,brain surgery, trauma, atrophy due to neurodegenerative disease such as frontotemporal degeneration; or other causes), with the exception of age related changes (e.g. mild-moderate cerebral volume loss) on either side and prior surgery that involved only the skull but not the brain
- Vascular encephalopathy, defined as Fazekas grade 2 or lower
- Any history of having been unconscious related to TBI or "medical condition" > 20 minutes or have had any head-injury resulting in an overnight hospital stay
- Any history of a medical event requiring resuscitation in which examinee was non-responsive for > 15 minutes
- Currently receiving chemotherapy treatment, or have received chemotherapy treatment in the past 2 months
- Any history of ECT or radiation to the CNS
- Currently diagnosed with substance abuse or dependence, or have carried any substance abuse or dependence diagnosis in the past year (> 1 year in remission diagnoses are ok)
- A current average alcohol consumption of 4 or more units per day. Long term alcohol abusers are excluded as well (e.g., abused substance for more than 10 years)
- Currently taking medication that might impact test performance (i.e. anti- convulsants, antipsychotics, benzodiazepines, psychostimulants, opioids, tricyclic Antidepressants, Oxybutynin)
- Disruptive behavior or insufficient compliance with testing to ensure a valid assessment
- Non-valid health insurance in USA
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Compare performance of patients with Mild Cognitive Impairment
Time Frame: Feb-2020 until Dec-2021
|
Create a database of digital cognitive assessment data in combination with neuroimaging data of patients with mild cognitive impairment to: Compare performance of patients with Mild Cognitive Impairment (MCI) to normative data of the healthy US population and characterize a MCI cognitive profile.
|
Feb-2020 until Dec-2021
|
|
Derive correlations between parameters
Time Frame: Feb-2020 until Dec-2021
|
Create a database of digital cognitive assessment data in combination with neuroimaging data of patients with mild cognitive impairment to: Derive correlations between parameters derived from MRI images (NeuroQuant scores) and the digital cognitive data.
|
Feb-2020 until Dec-2021
|
|
Identify (combinations of) parameters
Time Frame: Feb-2020 until Dec-2021
|
Create a database of digital cognitive assessment data in combination with neuroimaging data of patients with mild cognitive impairment to: Identify (combinations of) parameters that are relevant to classify MCI patients vs healthy controls.
|
Feb-2020 until Dec-2021
|
|
Explore predictive values
Time Frame: Feb-2020 until Dec-2021
|
Create a database of digital cognitive assessment data in combination with neuroimaging data of patients with mild cognitive impairment to: Explore predictive value of combination of neuroimaging and digital cognitive outcome parameters to predict MCI to Alzheimer's disease conversion.
|
Feb-2020 until Dec-2021
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Exploratory analysis to find new outcome measures from the raw input data of the digital cognitive tests.
Time Frame: Feb-2020 until Dec-2021
|
Feb-2020 until Dec-2021
|
|
Evaluate the performance of ISC scoring algorithms.
Time Frame: Feb-2020 until Dec-2021
|
Feb-2020 until Dec-2021
|
|
To explore usability aspects of ISC with MCI patients.
Time Frame: Feb-2020 until Dec-2021
|
Feb-2020 until Dec-2021
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- ICBE-2-34585
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MCI
-
NCT07512193Not yet recruiting
-
NCT06633978Recruiting
-
NCT06470074Not yet recruiting
-
NCT03189485Active, not recruitingMCI | Normal Controls
-
NCT07196592Not yet recruitingMCI-AD, Early Stage Alzheimer's Disease
-
NCT07297121Not yet recruitingDementia | Mild Cognitive Impairment (MCI) | MCI
Clinical Trials on IntelliSpace Cognition
-
NCT03801382CompletedCognitive Functioning of Healthy Individuals
-
NCT04729257CompletedCognitive Functioning of Healthy Individuals
-
NCT05239377CompletedProstate Cancer
-
NCT02045147Completed
-
NCT03052712TerminatedStroke | Parkinson Disease | Alzheimer Disease | Traumatic Brain Injury | Huntington Disease | Frontal Dementia
-
NCT04562844RecruitingAssessment and Rehabilitation of Social Cognition in People With Traumatic Brain Injury (CogniSo-TC)Cognition Disorder | Head Injury Trauma
-
NCT06828471RecruitingHuntington's Disease (HD)
-
NCT07602712Not yet recruitingSocial Cognition | Schizophrenia Spectrum Disorders